Paraguay
Tuberculosis profile
Population  2013 6.8 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.2 (0.18–0.22) 2.9 (2.6–3.2)
Mortality (HIV+TB only) 0.065 (0.053–0.078) 0.96 (0.78–1.1)
Prevalence  (includes HIV+TB) 4 (2–6.7) 59 (30–99)
Incidence  (includes HIV+TB) 3 (2.9–3.2) 44 (42–47)
Incidence (HIV+TB only) 0.31 (0.29–0.33) 4.6 (4.2–4.9)
Case detection, all forms (%) 75 (71–78)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 0.3 (0–1.7) 15 (6.1–28)
MDR-TB cases among notified pulmonary
TB cases
6 (0–32) 51 (21–97)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 1 426   143
Pulmonary, clinically diagnosed 435   40
Extrapulmonary 208   3
       
Total new and relapse 2 255    
Previously treated, excluding relapses 165    
Total cases notified 2 420    
Among 2 255 new and relapse cases:
183 (8%) cases aged under 15 years; male:female ratio: 2.3
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 267 (19%) 117 (33%) 384
Laboratory-confirmed RR-/MDR-TB cases     8
Patients started on MDR-TB treatment     5
TB/HIV 2013 Number (%)
TB patients with known HIV status 1 815 (75)
HIV-positive TB patients 178 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 66 (37)
HIV-positive TB patients on antiretroviral therapy (ART) 121 (68)
HIV-positive people screened for TB 381  
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 70
Previously treated cases, excluding relapse, registered in 2012 54
HIV-positive TB cases, all types, registered in 2012 30
RR-/MDR-TB cases started on second-line treatment in 2011 100
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.0
Culture (per 5 million population) 9.6
Drug susceptibility testing (per 5 million population) 0.7
Sites performing Xpert MTB/RIF 2
Is second-line drug susceptibility testing available? Yes, in country
Financing TB control 2014  
National TB programme budget (US$ millions) 3.9
% Funded domestically 34%
% Funded internationally 32%
% Unfunded 34%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-03-06 Data: www.who.int/tb/data